ARI-3037MO

DRUG3 trials

Sponsors

Arisaph Pharmaceuticals Inc

Conditions

HyperlipidemiaHypertriglyceridemiaNonalcoholic Steatohepatitis

Phase 2

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

CompletedNCT02250105

Arisaph Pharmaceuticals IncHypertriglyceridemia

Start: 2014-09-30End: 2016-06-30Updated: 2016-08-08

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

Arisaph Pharmaceuticals IncHyperlipidemia

Start: 2015-08-31End: 2016-12-31Target: 176Updated: 2016-08-08

A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis

Arisaph Pharmaceuticals IncNonalcoholic Steatohepatitis

Start: 2015-10-31End: 2016-12-31Updated: 2016-08-08